Amneal Pharmaceuticals Inc (AMRX)
6.45
+0.01
(+0.16%)
USD |
NASDAQ |
May 24, 16:00
6.45
0.00 (0.00%)
After-Hours: 20:00
Amneal Pharmaceuticals Net Income (Quarterly): -91.64M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -91.64M |
| December 31, 2023 | -98.65M |
| September 30, 2023 | 9.682M |
| June 30, 2023 | 11.92M |
| March 31, 2023 | -6.943M |
| December 31, 2022 | -4.333M |
| September 30, 2022 | -2.689M |
| June 30, 2022 | -120.81M |
| March 31, 2022 | -2.156M |
| December 31, 2021 | -6.377M |
| September 30, 2021 | -4.237M |
| June 30, 2021 | 14.53M |
| March 31, 2021 | 6.706M |
| December 31, 2020 | -3.037M |
| Date | Value |
|---|---|
| September 30, 2020 | -8.975M |
| June 30, 2020 | -12.00M |
| March 31, 2020 | 115.07M |
| December 31, 2019 | -32.13M |
| September 30, 2019 | -265.01M |
| June 30, 2019 | -16.90M |
| March 31, 2019 | -47.88M |
| December 31, 2018 | -8.768M |
| September 30, 2018 | 6.952M |
| June 30, 2018 | -219.44M |
| March 31, 2018 | 51.54M |
| December 31, 2017 | 61.57M |
| September 30, 2017 | 26.78M |
| June 30, 2017 | 37.45M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-265.01M
Minimum
Sep 2019
115.07M
Maximum
Mar 2020
-25.90M
Average
-5.355M
Median
Net Income (Quarterly) Benchmarks
| Fate Therapeutics Inc | -48.00M |
| Ocular Therapeutix Inc | -64.85M |
| Editas Medicine Inc | -61.95M |
| AnaptysBio Inc | -43.94M |
| AEON Biopharma Inc | -- |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 659.19M |
| Total Expenses (Quarterly) | 575.96M |
| EPS Diluted (Quarterly) | -0.30 |
| Enterprise Value | 4.624B |
| Gross Profit Margin (Quarterly) | 36.11% |
| Profit Margin (Quarterly) | -13.90% |
| Earnings Yield | -8.68% |
| Operating Earnings Yield | 19.36% |
| Normalized Earnings Yield | -4.878 |